BFC Planning’s Outlook Therapeutics OTLK Stock Holding History
Bought
Maintained
Sold
Other funds holding OTLK
BFC Planning's OTLK Position: Q3 2026 in Review
BFC Planning held its Outlook Therapeutics (OTLK) position steady in Q3 2026 at 61 shares worth $35. The position accounts for ﹤0.01% of the portfolio, ranked #3430.
BFC Planning first reported a position in OTLK in Q3 2024 and has held it in 9 quarters since. The position peaked at $326 in Q3 2024. 61 funds tracked by Wall St. Rank hold OTLK as of Q3 2026.
- BFC Planning held 61 shares of Outlook Therapeutics worth $35 as of Q3 2026.
- BFC Planning left its Outlook Therapeutics share count unchanged in Q3 2026.
- Outlook Therapeutics made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #3430 holding.
- BFC Planning first reported a position in Outlook Therapeutics in Q3 2024 and has held it in 9 quarters since.
- BFC Planning's Outlook Therapeutics position peaked at $326 in Q3 2024.
- 61 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q3 2026.
Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.